Published in Obesity and Diabetes Week, March 6th, 2006
The inhibition of fatty acid synthase as a means to control obesity has been a cornerstone of FASgen's extensive research into therapeutics to treat obesity. In parallel, the company also announced the award and issuance of its Eurasian patent, "Stimulation of CPT-1 as a Means to Reduce Weight." Stimulation of CPT-1 has been demonstrated to regulate fatty acid oxidation and the consequent weight loss that follows. FASgen's compounds have been shown to work at both the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.